# US 2009/0270333 A1 · Methods of using motilin homologs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270333 A1
- Document ID: US20090270333A1
- Status: Published application
- Kind: A1
- Application number: 12/075,821
- Filed: 2008-03-13
- Published: 2009-10-29
- Earliest claimed: 1997-03-24
- Assignees: ZymoGenetics, Inc.
- Inventors: Paul O. Sheppard; Theresa A. Deisher; Paul D. Bishop; Stephen R. Jaspers; Virender M. Labroo
- Web page: https://patentgrep.com/patent/US20090270333A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.

## Claims

### Claim 1

An isolated polynucleotide molecule encoding a polypeptide selected from the group consisting of:
(a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 70 to nucleotide 111;
(b) allelic variants of (a);
(c) orthologs of (a) and (b); and
(d) degenerate nucleotide sequences of (a), (b) or (c).

### Claim 2

An isolated polynucleotide molecule encoding a polypeptide selected from the group consisting of:
(a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 70 to nucleotide 120;
(b) allelic variants of (a);
(c) orthologs of (a) or (b); and
(d) degenerate nucleotide sequences of (a), (b) or (c).

### Claim 3

An isolated polynucleotide molecule encoding a polypeptide selected from the group consisting of:
(a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 70 to nucleotide 351;
(b) allelic variants of (a);
(c) orthologs of (a) or (b); and
(d) degenerate nucleotide sequences of (a), (b) or (c).

### Claim 4

An isolated polynucleotide molecule encoding a polypeptide selected from the group consisting of:
(a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 111;
(b) allelic variants of (a);
(c) orthologs of (a) or (b); and
(d) degenerate nucleotide sequences of (a), (b) or (c).

### Claim 5 (depends on 4)

The isolated polynucleotide molecule of claim 4, wherein said polynucleotide molecule further comprises the nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 351.

### Claim 6 (depends on 1)

The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.

### Claim 7

An expression vector comprising the following operably linked elements:
a transcription promoter;
a DNA segment selected from the group consisting of:
(a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 70 to nucleotide 111;
(b) allelic variants of (a);
(c) orthologs of (a) or (b); and
(d) degenerate nucleotide sequences of (a), (b) or (c);
a transcription terminator.

### Claim 8 (depends on 7)

A cultured cell into which has been introduced an expression vector according to claim 7, wherein said cell expresses the polypeptide encoded by the DNA segment.

### Claim 9

An isolated polypeptide selected from the group consisting of:
(a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 24 to residue 37;
(b) allelic variants of (a); and
(c) orthologs of (a) or (b).

### Claim 10

An isolated polypeptide selected from the group consisting of:
(a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 24 to 41;
(b) allelic variants of (a); and
(c) orthologs of (a) or (b).

### Claim 11

An isolated polypeptide selected from the group consisting of:
(a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 24 to residue 117;
(b) allelic variants of (a); and
(c) orthologs of (a) or (b).

### Claim 12

An isolated polypeptide selected from the group consisting of:
(a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 1 to residue 37;
(b) allelic variants of (a); and
(c) orthologs of (a) or (b).

### Claim 13 (depends on 9)

The isolated polypeptide of claim 9, wherein said polypeptide molecules further comprises an amino acid sequence as shown in SEQ ID NO: 2 from residue 1 to residue 117.

### Claim 14 (depends on 9)

A pharmaceutical composition comprising purified polypeptide according to claim 9, in combination with a pharmaceutically acceptable vehicle.

### Claim 15

An antibody that binds to an epitope of a polypeptide selected from the group consisting of:
(a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 24 to residue 117;
(b) allelic variants of (a); and
(c) orthologs of (a) or (b).

### Claim 16 (depends on 7)

A method of producing zsig33 polypeptide comprising:
culturing a cell into which has been introduced an expression vector according to claim 7, whereby said cell expresses a polypeptide encoded by the DNA segment; and
recovering the polypeptide.

### Claim 17

A method of stimulating gastric motility comprising administering to a mammal in need thereof, an amount of a pharmaceutical composition comprising a polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 24 to residue 37, sufficient to increase transit time or gastric emptying of an ingested substance.

### Claim 18 (depends on 17)

The method of claim 17, wherein the transit time or gastric emptying is measured using a radiolabeled substance.

### Claim 19

A method of stimulating nutrient absorption in a mammal in need thereof comprising administering to the mammal in need thereof an effective amount of a pharmaceutical composition comprising a polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 24 to residue 37.

### Claim 20 (depends on 19)

The method of claim 19, wherein the nutrient is glucose.
